Buy & Sell Crispr Therapeutics AG (CRSP) – Crispr Therapeutics AG Price Today
Aura AI Summary
Key Stats
- $4.67BMarket Cap
- HealthSector
- -28.18%3M Drawdown
- $3.01BEnterprise Value
- -Dividend Yield
- 69 daysTypical Hold Time
Crispr Therapeutics AG (CRSP) is currently valued at a market capitalization of $4.67B, with an enterprise value of $3.01B. Over the past 52 weeks, Crispr Therapeutics AG has traded between a low of $36.29 and a high of $76.78, highlighting its annual price range. Over the past three months, Crispr Therapeutics AG has recorded a drawdown of -28.18%, reflecting recent price volatility. On average, investors hold Crispr Therapeutics AG for approximately 69 days, indicating typical investor behavior on the platform.
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Most Recent News
PropTech market to grow to $165B by 2035, driven by AI, smart buildings, and cloud tech adoption.
The PropTech market, valued at $43 billion in 2025, is projected to reach $165 billion by 2035 with a CAGR of 13.9%. Growth is fueled by AI-powered property management, smart building technologies, cloud computing, and blockchain in real estate trans...
Jyske Realkredit releases preliminary data on early bond redemptions for investor review.
Jyske Realkredit A/S has published preliminary data on early redemptions (prepayments) of its issued bonds, as required by the Capital Markets Act. This information is intended to keep investors informed about bond prepayment activity and is availabl...
Bill Gates Foundation sells last $3.2B Microsoft stake, ending decades-long investment.
The Bill & Melinda Gates Foundation completed its exit from Microsoft by selling its remaining 7.7 million shares worth about $3.2 billion in early 2026. This move follows a phased reduction starting two years ago, with the largest sale in late 2025....